Riensche Melissa R, Graves Thomas K, Schaeffer David J
Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
J Feline Med Surg. 2008 Apr;10(2):160-6. doi: 10.1016/j.jfms.2007.10.005. Epub 2007 Dec 20.
To determine if routine pre-treatment clinical data can be used to predict the development of overt renal insufficiency following treatment of feline hyperthyroidism, we studied retrospectively all non-azotemic cats undergoing treatment for hyperthyroidism at our hospital. Medical records were reviewed for signalment, clinical signs, and serum biochemical, hematologic and urinalysis parameters before and after treatment for hyperthyroidism. Two groups - cats that developed post-treatment renal insufficiency, and those that did not - were compared. No significant differences could be detected between the groups with respect to the parameters measured. Our study suggests that the results of routine pre-treatment clinical data cannot be used to reliably predict renal function after treatment for hyperthyroidism, validating the necessity of a methimazole trial prior to definitive therapy. The widely held belief that cats with pre-treatment urine specific gravity>1.035 are at less risk for development of renal azotemia after treatment of hyperthyroidism seems unwarranted.
为了确定常规治疗前的临床数据是否可用于预测猫甲状腺功能亢进症治疗后明显肾功能不全的发生，我们对我院所有接受甲状腺功能亢进症治疗的非氮质血症猫进行了回顾性研究。查阅了甲状腺功能亢进症治疗前后的病历，包括特征、临床症状以及血清生化、血液学和尿液分析参数。比较了两组猫——治疗后出现肾功能不全的猫和未出现肾功能不全的猫。在测量的参数方面，两组之间未发现显著差异。我们的研究表明，常规治疗前临床数据的结果不能可靠地预测甲状腺功能亢进症治疗后的肾功能，这证实了在确定治疗之前进行甲巯咪唑试验的必要性。普遍认为治疗前尿比重>1.035的猫在甲状腺功能亢进症治疗后发生肾性氮质血症的风险较低，这一观点似乎没有依据。
